Avrobio (AVRO) PT Lowered to $6 at Needham & Company, "Buy" Rating Maintained, "Encouraged by Evolving ARV-RD-04 Results" May 17, 2022 10:40AM
Avrobio Inc. (AVRO) PT Lowered to $2 at Stifel Mar 17, 2022 04:34PM
Needham & Company Reiterates Avrobio (AVRO) at Outperform, $8 PT, Remains Supporter of Company's LV Based Gene Therapy Programs Mar 17, 2022 10:14AM
Avrobio's (AVRO) ARV-RD-04 Phase 1/2 Provide Proof-of-Concept, Represent a Free Call Option on Stock - Mizuho Securities Feb 9, 2022 05:16PM
AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel Jan 4, 2022 10:37AM